SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:prod.swepub.kib.ki.se:152555891"
 

Search: onr:"swepub:oai:prod.swepub.kib.ki.se:152555891" > Landscape of BCL2 R...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Kotmayer, L (author)

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • 2023-03-18
  • MDPI AG,2023

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:152555891
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:152555891URI
  • https://doi.org/10.3390/ijms24065802DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and D103Y, sensitive (10−4) screening for the most common BCL2 mutations G101V and D103Y was performed in 67 R/R CLL patients during venetoclax single-agent or venetoclax–rituximab combination therapy. With a median follow-up time of 23 months, BCL2 G101V and D103Y were detected in 10.4% (7/67) and 11.9% (8/67) of the cases, respectively, with four patients harboring both resistance mutations. Ten out of eleven patients carrying BCL2 G101V and/or D103Y experienced relapse during the follow-up period, representing 43.5% of the cases (10/23) showing clinical signs of disease progression. All BCL2 G101V or D103Y variants were detected in patients receiving venetoclax as a continuous single-agent treatment while these mutations were not observed during or after fixed-duration venetoclax therapy. Targeted ultra-deep sequencing of BCL2 uncovered three additional variants in four patient samples obtained at relapse, suggesting convergent evolution and implying a cooperating role of BCL2 mutations in driving venetoclax resistance. This cohort is the largest R/R CLL patient population reported to date in which BCL2 resistance mutations were investigated. Our study demonstrates the feasibility and clinical value of sensitive screening for BCL2 resistance mutations in R/R CLL.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Laszlo, T (author)
  • Mikala, G (author)
  • Kiss, R (author)
  • Levay, L (author)
  • Hegyi, LL (author)
  • Grof, S (author)
  • Nagy, T (author)
  • Barna, G (author)
  • Farkas, P (author)
  • Weisinger, J (author)
  • Nagy, Z (author)
  • Balogh, A (author)
  • Masszi, T (author)
  • Demeter, J (author)
  • Sulak, A (author)
  • Kohl, Z (author)
  • Alizadeh, H (author)
  • Egyed, M (author)
  • Pettendi, P (author)
  • Gergely, L (author)
  • Plander, M (author)
  • Pauker, Z (author)
  • Masszi, A (author)
  • Matolcsy, AKarolinska Institutet (author)
  • Szasz, R (author)
  • Bodor, C (author)
  • Alpar, D (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:International journal of molecular sciences: MDPI AG24:61422-0067

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view